Recruiting

ATTO-3712 for Safety and Tolerability in Atopic Dermatitis and Healthy Volunteers

What is being tested

ATTO-3712

+ Placebo

Drug

Who is being recruted

Dermatitis+12

+ Dermatitis, Atopic

+ Hypersensitivity

From 18 to 65 Years

+34 Eligibility Criteria

See all eligibility criteria

How is the trial designed

Treatment Study

Placebo-ControlledPhase 1

Interventional

Study Start: October 2025

See protocol details

Summary

Principal SponsorAttovia Therapeutics Inc

Study ContactMalinda Longphre, PhD

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Study start date: October 22, 2025

Actual date on which the first participant was enrolled.

This clinical trial explores a new drug called ATTO-3712 to see how safe and tolerable it is, and how it behaves in the body. It is aimed at both healthy adults and adults suffering from atopic dermatitis, a skin condition that causes itchy and inflamed skin. The study is important because it could lead to better treatment options for people with this condition, which can be quite uncomfortable and challenging to manage. Participants in this study will receive the drug ATTO-3712 either as a single dose or multiple doses. Healthy volunteers will help researchers understand how the drug interacts with the body over time, while those with atopic dermatitis will help determine its effects on the skin condition. The study will measure safety and tolerability by monitoring participants closely, and will also look at biomarkers in the blood to assess how the body processes the drug. This process will help ensure the drug is safe and effective for future use.

Official TitleA Phase 1, Randomized, Double-Blind, Placebo-Controlled, Multi-Part, Single Ascending Dose and Multiple Ascending Dose Study to Assess the Safety, Tolerability, and Pharmacokinetics of ATTO-3712 in Healthy Adult Volunteers and Patients With Atopic Dermatitis

NCT07205081

Principal SponsorAttovia Therapeutics Inc

Study ContactMalinda Longphre, PhD

Last updated: January 28, 2026

Sourced from a government-validated database.Claim as a partner

Protocol

This section provides details of the study plan, including how the study is designed and what the study is measuring.

Design Details

72 patients to be enrolled

Total number of participants that the clinical trial aims to recruit.

Treatment Study

These studies test new ways to treat a disease, condition, or health issue. The goal is to see if a new drug, therapy, or approach works better or has fewer side effects than existing options.

Eligibility

Researchers look for people who fit a certain description, called eligibility criteria: person's general health condition or prior treatments.

Conditions

Criteria

Any sex

Biological sex of participants that are eligible to enroll.

From 18 to 65 Years

Range of ages for which participants are eligible to join.

Healthy volunteers allowed

If individuals who are healthy and do not have the condition being studied can participate.

Conditions

Pathology

DermatitisDermatitis, AtopicHypersensitivityHypersensitivity, ImmediateImmune System DiseasesCongenital, Hereditary, and Neonatal Diseases and AbnormalitiesPruritusSigns and SymptomsSkin DiseasesSkin Diseases, GeneticSkin ManifestationsPathological Conditions, Signs and SymptomsSkin and Connective Tissue DiseasesSkin Diseases, EczematousGenetic Diseases, Inborn

Criteria

13 inclusion criteria required to participate

vIGA-AD score of ≥ 3 at Screening and Day 1

≥10% of body surface area (BSA) affected by AD at Screening and Day 1

Use of topical bland emollient (moisturizer) at least once daily for at least 5 of the 7 days immediately before Day 1 and agrees to continue using that same emollient at the same frequency throughout the study

Any sex or gender who is 18 to 65 years old, inclusive, at Screening.

Show More Criteria

21 exclusion criteria prevent from participating

Active or latent tuberculosis infection

Smoking more than 20 cigarettes (or cigars, cigarillos, or e-cigarettes equivalent) per day

Presence of skin comorbidities that may interfere with study assessments

Has taken prescription medication for the treatment of AD or other prohibited medication within the restricted time limits (defined in the protocol)

Show More Criteria

Study Plan

Find out more about all the medication administered in this study, their detailed description and what they involve.

Treatment Groups

Study Objectives

6 intervention groups are designated in this study

50% chance of being blinded to the placebo group

Treatment Groups

Group I

Experimental

ATTO-3712 administered to dose level cohorts in multiple SC doses

Group II

Experimental

ATTO-3712 Dose level cohorts receiving a single dose IV

Group III

Experimental

ATTO-3712 dose level cohorts receiving a single dose SC

Group IV

Placebo

Placebo preparation to match Experimental Arm administered in multiple SC doses

Group 5

Placebo

Placebo preparation to match Experimental Arm with single dose IV

Group 6

Placebo

Placebo preparation to match Experimental Arm with single dose SC

Study Objectives

Primary Objectives

Secondary Objectives

Study Centers

These are the hospitals, clinics, or research facilities where the trial is being conducted. You can find the location closest to you and its status.

This study has 1 location

Recruiting

Altasciences

Montreal, CanadaOpen Altasciences in Google Maps

Recruiting

One Study Center